Comparative Analysis of Bioactivity of the Russian-Made Antitumor Substances of the Nitrosourea Group


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

We performed an in vivo comparative study of activity of three substances of the nitrosourea group produced in Russia. All substances demonstrated high antitumor activity against various solid and leukemic tumors. Aranosa significantly enhanced life duration in mice with leukemia (by 65-194%) and inhibited the growth of solid tumors (by 49-99.6%). Lisomustine and ormustine showed higher activity than aranose. Single administration of lisomustine increased life span of mice (by 22-114%) and resulted in cure of all animals in four models: lymphoblastic leukemia L-1210, lymphocytic leukemia P-388, Lewis lung carcinoma, and cervical cancer RShM-5. After ormustine treatment, full recovery was observed only in groups with lymphocytic leukemia P-388 and cervical cancer RShM-5. These findings attest to higher activity of lisomustine in the studied models.

作者简介

N. Bunyatyan

I. M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of the Russian Federation; Research Center for Expert Evaluation of Medical Products, Ministry of Health of the Russian Federation

编辑信件的主要联系方式.
Email: ndbun@mail.ru
俄罗斯联邦, Moscow; Moscow

N. Oborotova

I. M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of the Russian Federation; N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: ndbun@mail.ru
俄罗斯联邦, Moscow; Moscow

L. Nikolaeva

I. M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of the Russian Federation; N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: ndbun@mail.ru
俄罗斯联邦, Moscow; Moscow

N. Saprykina

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: ndbun@mail.ru
俄罗斯联邦, Moscow

L. Borisova

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: ndbun@mail.ru
俄罗斯联邦, Moscow

M. Kiseleva

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: ndbun@mail.ru
俄罗斯联邦, Moscow

A. Prokof’ev

I. M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of the Russian Federation; Research Center for Expert Evaluation of Medical Products, Ministry of Health of the Russian Federation

Email: ndbun@mail.ru
俄罗斯联邦, Moscow; Moscow


版权所有 © Springer Science+Business Media, LLC, part of Springer Nature, 2019
##common.cookie##